A bill to help ensure the safety of U.S. drug supplies has sailed through the House. The
Food and Drug Administration had lobbied hard for the measure. It reauthorizes user-fee programs that help the agency pay for reviews of new medicines. It also gives the FDA flexibility so regulators can target the most problematic manufacturers, regardless of whether they are in the United States or abroad. The Senate passed a similar bill last week. The two chambers still have some differences to iron out in a conference committee before they can send the bill to the president.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.